Sage Therapeutics Announces Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
Revenue: Net revenue from sales of ZULRESSO was $1.6 million in the second quarter of 2021 compared to $1.1 million in the same period of 2020.
- Revenue: Net revenue from sales of ZULRESSO was $1.6 million in the second quarter of 2021 compared to $1.1 million in the same period of 2020.
- Restructuring Expenses: Sage had no restructuring expenses in the second quarter of 2021 compared to $28.4 million in the second quarter of 2020.
- Sage anticipates cash, cash equivalents, and marketable securities of more than $1.7 billion at end of 2021.
- Sage will host a conference call and webcast today, Tuesday, August 3, at 8:00 am ET to discuss its second quarter 2021 financial results and recent corporate updates.